ArriVent BioPharma, Inc. (NASDAQ:AVBP – Get Free Report) shares traded down 8.3% during mid-day trading on Tuesday . The stock traded as low as $20.36 and last traded at $20.60. 119,302 shares changed hands during trading, a decline of 26% from the average session volume of 161,620 shares. The stock had previously closed at $22.47. […]
ArriVent BioPharma, Inc. (NASDAQ:AVBP – Get Free Report)’s stock price dropped 8.3% during trading on Tuesday . The stock traded as low as $20.36 and last traded at $20.60. Approximately 119,302 shares were traded during trading, a decline of 26% from the average daily volume of 161,620 shares. The stock had previously closed at $22.47. […]
Wall Street Breakfast: The Week Ahead seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
(Bloomberg) Drug developers are capitalizing on the industry’s momentum by tapping public investors for the first time, as corporate takeovers and a welcoming market lift optimism about biotechnology.Most Read from BloombergCitadel Among Hedge Funds That Got Morgan Stanley’s Block-Trading LeaksTesla Asks Which Jobs Are Critical, Stoking Layoff FearsChina Replaces Top Markets Regulator as Xi Tries to End RoutUS Commercial Real Estate Contagion Is Now Moving to EuropeHaley Loses Nevada Primary
Biotech IPOs Jump More Than 20% as Momentum Builds for Listings bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.